-
公开(公告)号：US20190298810A1
公开(公告)日：2019-10-03
申请号：US15760656
申请日：2016-09-27
发明人： Rajendra PRADHAN , Xiang GAO
摘要： A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
-
2.发明申请公开(公告)号：US20180237509A1
公开(公告)日：2018-08-23
申请号：US15762207
申请日：2016-09-23
发明人： Marina NORIS , Giuseppe REMUZZI , Carmine PECORARO
IPC分类号： C07K16/18 , A61K45/06 , A61K39/395 , A61K39/095
CPC分类号： C07K16/18 , A61K39/095 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2039/55 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： Provided are methods for clinical treatment of an ADAMTS 13 deficiency by administering an anti-C5 antibody, or antigen binding fragment thereof. Also, provided are methods for clinical treatment of congenital Thrombotic Thrombocytopenic Purpura by administering an anti-C5 antibody, or antigen binding fragment thereof.
-
公开(公告)号：US20240279320A1
公开(公告)日：2024-08-22
申请号：US18568011
申请日：2022-06-09
发明人： Laura Marie Gault , Adrian Markus Kielhorn , Sanjay Nandkumar Rakhade , Usharbudh Shivraj Sohur
CPC分类号： C07K16/18 , A61P17/00 , A61P21/00 , C07K16/283 , A61K2039/505 , A61K2039/545
摘要： Provided are dosages and methods for clinical treatment of dermatomyositis (DM), particularly severe and/or refractory DM, in human patients using an anti C5 antibody, or antigen binding fragment thereof (e.g., such as ravulizumab (ULTOMIRIS®)).
-
公开(公告)号：US12025621B2
公开(公告)日：2024-07-02
申请号：US17161783
申请日：2021-01-29
CPC分类号： G01N33/6893 , C07K16/18 , G01N33/6863 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
-
公开(公告)号：US11965884B2
公开(公告)日：2024-04-23
申请号：US16342245
申请日：2017-10-19
发明人： Mark Dysinger , Mark Ma , Bruce A. Andrien
IPC分类号： G01N33/543
CPC分类号： G01N33/54393 , G01N33/54313 , G01N33/54353 , G01N2333/4716
摘要： A method of quantitating free (unbound) human C5 complement protein (C5) from a sample comprising: binding biotinylated anti-C5 capture antibody to strepavidin-coated particles; capturing the free (unbound) C5 in the sample; detecting the captured free C5; and quantitating the captured free C5 using laser-induced fluorescence detection; wherein the method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument.
-
公开(公告)号：US20240100088A1
公开(公告)日：2024-03-28
申请号：US18272308
申请日：2022-01-31
发明人： Justin Lockheart Burt , David Jenson Chen , Todd Anthony Stutzman , Allissa Robin Kerner , Joseph Michael Schnitz , Raj Ramnik Jain
CPC分类号： A61K33/24 , A61K9/2054 , A61K9/2095 , A61K9/2893
摘要： This disclosure relates to novel formulations of bis-choline tetrathiomolybdate useful for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD). For example, this disclosure relates to low dose formulations of bis-choline tetrathiomolybdate.
-
7.发明公开公开(公告)号：US20240092881A1
公开(公告)日：2024-03-21
申请号：US18272906
申请日：2022-01-18
发明人： Gin-Fu Chen , Zeeshan Khawaja
IPC分类号： C07K16/18 , A61K39/395 , A61K45/06 , A61P7/02
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61P7/02 , A61K2039/505
摘要： Provided are methods for clinical treatment of complement-mediated TMA (CM-TMA) (e.g., CM-TMA associated with a trigger, such as autoimmune condition, an infection, a transplant, one or more drugs, or malignant hypertension), using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
-
8.发明公开公开(公告)号：US20240052327A1
公开(公告)日：2024-02-15
申请号：US18032973
申请日：2021-10-21
发明人： Meghan DeWitt , Siguang Sui , Rahul Godawat , Sarah Berendes
IPC分类号： C12N9/16
CPC分类号： C12N9/16 , C12Y301/03001 , C07K2319/30
摘要： Featured are methods of manufacturing recombinant alkaline phosphatases, such as asfotase alfa, that provide more precise quality control over total sialic acid content (TSAC) concentration in the final product by measuring TSAC concentration during fermentation and adjusting downstream production steps in response.
-
公开(公告)号：US20230416344A1
公开(公告)日：2023-12-28
申请号：US17918863
申请日：2021-04-16
申请人： Alexion Pharmaceuticals, Inc. , Assistance Publique, Hopitaux de Paris , Djillali Annane , Veronique Fremeaux-Bacchi , Regis Peffault De Latour
发明人： Sharon Barr , Derek Dunn , Xiang Gao , Shamsah D. Kazani , Michele Mercuri , Jonathan Monteleone , Stephan Ortiz , Scott T. Rottinghaus , Martine Zimmermann , Djillali Annane , Veronique Fremeaux-Bacchi , Regis Peffault De Latour
IPC分类号： C07K16/18 , A61K45/06 , A61P31/14 , G01N33/569
CPC分类号： C07K16/18 , A61K45/06 , A61P31/14 , G01N2469/20 , C07K2317/76 , C07K2317/24 , G01N33/56983
摘要： The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject. In addition, the present disclosure relates to, inter alia, a method of treating human patients inflicted with severe coronavirus disease-2019 (severe COVID-19) who is undergoing treatment with eculizumab. The method includes measuring a level of circulating component C5b-9 (membrane attack complex), in the patient's blood sample to titrate an effective eculizumab dose for the treatment of COVID-19.
-
公开(公告)号：US11807678B2
公开(公告)日：2023-11-07
申请号：US16358779
申请日：2019-03-20
发明人： Russell P. Rother
CPC分类号： C07K16/18 , A61K9/0019 , A61K39/3955 , A61K45/06 , A61K38/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/34
摘要： The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
-
-
-
-
-
-
-
-
-
搜索结果
342 条记录 (耗时 0.032 秒)
